概括
诸如拉和异二酸盐之类的血管扩张剂在急性充血性心力衰竭 (CHF) 患者中没有提高最大运动能力. 然而,它们在较低的运动强度下改善了血液动力学,可能会提高心血管疾病患者的耐受性.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在充血性心力衰竭 (CHF) 患者中,静止血液动力学得到了血管扩张剂的改善.
- 血管扩张剂对CHF运动血液动力学的影响尚不清楚.
研究的目的:
- 调查口服拉和异索二酸盐对心血管衰竭患者的运动血液动力学和运动能力的急性影响.
主要方法:
- 一个随机的,双盲的,安慰剂控制的研究.
- 22名患有II或III级慢性心血管炎的患者进行了自行车运动.
- 在服用氨酸/异索二酸盐或安慰剂之前和之后进行的测量.
主要成果:
- 在两组中,最大运动持续时间和氧气消耗量都没有变化.
- 在亚最大运动时,心脏指数增加,血管扩展剂组的系统血管阻力显著下降 (p <0.05).
- 在这两组中都没有观察到高峰运动时显著的血液动力学变化.
结论:
- 过敏地给予拉和异索二酸盐并没有提高CHF患者的最大运动能力.
- 血管扩张剂可以改善次最大运动血液动力学,可能增加在慢性心血管疾病中较低工作速度的运动耐受性.
更多相关视频
相关概念视频
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...


